Bio-Rad Laboratories Stock Price, News & Analysis (NYSE:BIO)

$251.94 2.22 (0.89 %)
(As of 12/18/2017 12:58 PM ET)
Previous Close$249.72
Today's Range$250.36 - $253.01
52-Week Range$177.68 - $273.87
Volume338,400 shs
Average Volume179,899 shs
Market Capitalization$7.50 billion
P/E Ratio80.02
Dividend YieldN/A
Beta0.97

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:BIO
CUSIP09057220
Phone510-724-7000

Debt

Debt-to-Equity Ratio0.15%
Current Ratio4.06%
Quick Ratio2.77%

Price-To-Earnings

Trailing P/E Ratio80.02
Forward P/E Ratio94.01
P/E Growth3.76

Sales & Book Value

Annual Sales$2.07 billion
Price / Sales3.63
Cash Flow$3.87 per share
Price / Cash65.10
Book Value$87.46 per share
Price / Book2.88

Profitability

Trailing EPS$0.79
Net Income$28.12 million
Net Margins1.15%
Return on Equity3.44%
Return on Assets2.34%

Miscellaneous

Employees8,250
Outstanding Shares29,760,000

Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories announced that its board has authorized a share buyback plan on Wednesday, November 29th 2017, which permits the company to buyback $250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings data on Thursday, November, 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.37. The medical research company earned $535 million during the quarter, compared to analyst estimates of $507.99 million. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The company's revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.62 EPS. View Bio-Rad Laboratories' Earnings History.

When will Bio-Rad Laboratories make its next earnings announcement?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Bio-Rad Laboratories.

Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2017?

3 analysts have issued 12 month target prices for Bio-Rad Laboratories' shares. Their forecasts range from $255.00 to $290.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $273.33 in the next year. View Analyst Ratings for Bio-Rad Laboratories.

What are Wall Street analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:

  • 1. According to Zacks Investment Research, "Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. " (12/13/2017)
  • 2. Jefferies Group LLC analysts commented, "Time to forget everything you thought you knew about BIO -- as two separate updates y'day included several "firsts" that add conviction to our bullish thesis: 1) 2020 rev & margin goals; 2) capital allocation plan opens the door for buybacks; 3) board shuffle / quality upgrade. Bottom line: the pathway to $300+ in 2-3 yrs just got a lot clearer & BIO's new shareholder-friendly behavior eliminates the rationale for a structural valuation discount, in our view." (3/14/2017)

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:

  • Norman D. Schwartz, Chairman of the Board, President, Chief Executive Officer (Age 71)
  • Christine A. Tsingos, Chief Financial Officer, Executive Vice President (Age 58)
  • John P. Goetz, Chief Operating Officer, Executive Vice President (Age 67)
  • Timothy Scott Ernst, Executive Vice President, General Counsel and Secretary (Age 57)
  • Michael Crowley, Executive Vice President, Global Commercial Operations (Age 55)
  • Shannon Hall, Executive Vice President, President, Life Science Group (Age 47)
  • John Hertia, Executive Vice President, President, Clinical Diagnostics Group (Age 61)
  • Giovanni Magni, Executive Vice President, Chief Strategy Officer (Age 60)
  • Ronald W. Hutton, Vice President, Treasurer (Age 59)
  • Alice N. Schwartz, Director (Age 90)

Who owns Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Atlanta Capital Management Co. L L C (5.32%), TimesSquare Capital Management LLC (2.24%), American Century Companies Inc. (1.91%), Wells Fargo & Company MN (1.81%), NWQ Investment Management Company LLC (0.97%) and Cramer Rosenthal Mcglynn LLC (0.95%). Company insiders that own Bio-Rad Laboratories stock include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.

Who sold Bio-Rad Laboratories stock? Who is selling Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, Cramer Rosenthal Mcglynn LLC, NWQ Investment Management Company LLC, Intrepid Capital Management Inc., Investment Counselors of Maryland LLC, Russell Investments Group Ltd., SG Americas Securities LLC and Tygh Capital Management Inc.. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.

Who bought Bio-Rad Laboratories stock? Who is buying Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Westfield Capital Management Co. LP, Claar Advisors LLC, TimesSquare Capital Management LLC, Asset Management One Co. Ltd., Citadel Advisors LLC, Epoch Investment Partners Inc. and Allianz Asset Management GmbH. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy Bio-Rad Laboratories stock?

Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of Bio-Rad Laboratories stock can currently be purchased for approximately $251.94.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $7.50 billion and generates $2.07 billion in revenue each year. The medical research company earns $28.12 million in net income (profit) each year or $0.79 on an earnings per share basis. Bio-Rad Laboratories employs 8,250 workers across the globe.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (BIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  170 (Thanks for Voting!)
Underperform Votes:  148 (Thanks for Voting!)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Rad Laboratories (NYSE:BIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $250.00$240.00$240.00$208.33
Price Target Upside: 5.05% downside4.53% upside4.53% upside3.06% downside

Bio-Rad Laboratories (NYSE:BIO) Consensus Price Target History

Price Target History for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017Wells Fargo & CompanyReiterated RatingOutperform$250.00 -> $290.00HighView Rating Details
9/18/2017Deutsche BankReiterated RatingBuy$255.00LowView Rating Details
7/14/2017Jefferies GroupReiterated RatingBuy$275.00LowView Rating Details
10/12/2016CL KingInitiated CoverageBuy$180.00N/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Bio-Rad Laboratories (NYSE:BIO) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE BIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$1.26N/AView Earnings Details
11/2/2017Q3 2017$0.54$0.91$507.99 million$535.00 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.27$0.41$477.76 million$500.05 millionViewListenView Earnings Details
2/23/2017Q416$1.03($0.70)$574.40 million$571.45 millionViewN/AView Earnings Details
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Bio-Rad Laboratories (NYSE:BIO) Earnings Estimates

2017 EPS Consensus Estimate: $3.22
2018 EPS Consensus Estimate: $4.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.41$0.41$0.41
Q2 20171$0.81$0.81$0.81
Q3 20171$0.26$0.26$0.26
Q4 20171$1.74$1.74$1.74
Q1 20181$1.04$1.04$1.04
Q2 20181$1.33$1.33$1.33
Q3 20181$1.05$1.05$1.05
Q4 20181$1.34$1.34$1.34
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bio-Rad Laboratories (NYSE:BIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bio-Rad Laboratories (NYSE BIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.29%
Institutional Ownership Percentage: 63.91%
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE BIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/14/2017Christine A TsingosCFOSell4,980$249.40$1,242,012.00View SEC Filing  
12/4/2017Michael CrowleyEVPSell1,000$258.39$258,390.00View SEC Filing  
11/30/2017James R. StarkVPSell746$270.51$201,800.46View SEC Filing  
11/14/2017Giovanni MagniEVPSell2,400$253.01$607,224.00View SEC Filing  
8/11/2017Michael CrowleyEVPSell700$215.91$151,137.00View SEC Filing  
3/7/2017Michael CrowleyEVPSell300$196.13$58,839.00View SEC Filing  
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Rad Laboratories (NYSE BIO) News Headlines

Source:
DateHeadline
GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in SessionGW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session
finance.yahoo.com - December 15 at 11:51 AM
Bio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 4,980 SharesBio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 4,980 Shares
www.americanbankingnews.com - December 14 at 8:52 PM
Protein Expression Market, 2023Protein Expression Market, 2023
finance.yahoo.com - December 14 at 3:44 PM
Bio-Rad Laboratories (BIO) Rating Increased to Strong-Buy at Zacks Investment ResearchBio-Rad Laboratories (BIO) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - December 13 at 4:46 PM
Global Protein Expression Market 2016-2023: Market is Expected to Grow from $1.4 Billion to $3.0 BillionGlobal Protein Expression Market 2016-2023: Market is Expected to Grow from $1.4 Billion to $3.0 Billion
www.benzinga.com - December 13 at 3:44 PM
Zacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $617.23 MillionZacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $617.23 Million
www.americanbankingnews.com - December 12 at 1:56 AM
 Analysts Expect Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $1.27 Per Share Analysts Expect Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $1.27 Per Share
www.americanbankingnews.com - December 10 at 11:32 PM
Bio-Rad Laboratories, Inc. (BIO) Receives Consensus Recommendation of "Buy" from AnalystsBio-Rad Laboratories, Inc. (BIO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 10 at 1:52 AM
ETFs with exposure to Bio-Rad Laboratories, Inc. : December 7, 2017ETFs with exposure to Bio-Rad Laboratories, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 3:47 PM
Outstanding Measures for Earnings Momentum Keep Bio Rad Laboratories (BIO) a Strong BuyOutstanding Measures for Earnings Momentum Keep Bio Rad Laboratories (BIO) a Strong Buy
investorplace.com - December 7 at 12:23 PM
Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 1:00 PM
Michael Crowley Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (BIO) StockMichael Crowley Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (BIO) Stock
www.americanbankingnews.com - December 4 at 9:02 PM
Bio-Rad (BIO) at a 52-Week High: Whats Driving the Stock?Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?
www.zacks.com - December 1 at 6:30 PM
Bio-Rad Laboratories, Inc. (BIO) VP James R. Stark Sells 746 SharesBio-Rad Laboratories, Inc. (BIO) VP James R. Stark Sells 746 Shares
www.americanbankingnews.com - November 30 at 8:22 PM
Best-in-Class Metrics for Earnings Growth Keep Bio Rad Laboratories (BIO) a Strong BuyBest-in-Class Metrics for Earnings Growth Keep Bio Rad Laboratories (BIO) a Strong Buy
investorplace.com - November 30 at 12:04 PM
Bio-Rad Laboratories (BIO) Earns "Outperform" Rating from Wells Fargo & CompanyBio-Rad Laboratories (BIO) Earns "Outperform" Rating from Wells Fargo & Company
www.americanbankingnews.com - November 29 at 7:30 PM
Bio-Rad Laboratories (BIO) to Repurchase $250.00 million in  Outstanding Stock Bio-Rad Laboratories (BIO) to Repurchase $250.00 million in Outstanding Stock
www.americanbankingnews.com - November 29 at 11:10 AM
BRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase ProgramBRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase Program
www.reuters.com - November 28 at 3:39 PM
Bio-Rad Labs (BIO) Announces $250M Stock BuybackBio-Rad Labs (BIO) Announces $250M Stock Buyback
www.streetinsider.com - November 28 at 3:39 PM
Bio-Rad Authorizes New $250 Million Share Repurchase ProgramBio-Rad Authorizes New $250 Million Share Repurchase Program
finance.yahoo.com - November 28 at 3:39 PM
Comparing Bio-Rad Laboratories (BIO) & ICU Medical (ICUI)Comparing Bio-Rad Laboratories (BIO) & ICU Medical (ICUI)
www.americanbankingnews.com - November 26 at 9:40 AM
Bio Rad Laboratories (BIO) a Strong Buy on High-Level Quant ScoreBio Rad Laboratories (BIO) a Strong Buy on High-Level Quant Score
investorplace.com - November 23 at 12:21 PM
$1.27 EPS Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter$1.27 EPS Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter
www.americanbankingnews.com - November 23 at 1:26 AM
Global Immunoassay Reagents and Devices Market Expected To Be Worth US$ 26.00 Billion By 2022Global Immunoassay Reagents and Devices Market Expected To Be Worth US$ 26.00 Billion By 2022
www.marketwatch.com - November 22 at 10:12 PM
Bio-Rad to Webcast Investor Day 2017Bio-Rad to Webcast Investor Day 2017
finance.yahoo.com - November 21 at 11:21 PM
Global high throughput screening market analysis and forecast to 2022 made available by Meticulous Research™Global high throughput screening market analysis and forecast to 2022 made available by Meticulous Research™
globenewswire.com - November 21 at 3:29 PM
Single Cell Analysis Market to Grow Owing to Rising Prevalence of Life Threatening Diseases Till 2024 | Million InsightsSingle Cell Analysis Market to Grow Owing to Rising Prevalence of Life Threatening Diseases Till 2024 | Million Insights
www.marketwatch.com - November 21 at 3:54 AM
Bio-Rad Laboratories, Inc. (BIO) Upgraded to B- by TheStreetBio-Rad Laboratories, Inc. (BIO) Upgraded to B- by TheStreet
www.americanbankingnews.com - November 19 at 8:16 PM
ETFs with exposure to Bio-Rad Laboratories, Inc. : November 17, 2017ETFs with exposure to Bio-Rad Laboratories, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 4:10 PM
Bio-Rad Laboratories, Inc. (BIO) EVP Sells $607,224.00 in StockBio-Rad Laboratories, Inc. (BIO) EVP Sells $607,224.00 in Stock
www.americanbankingnews.com - November 15 at 8:20 PM
Bio-Rad Laboratories, Inc. (BIO) Receives Average Recommendation of "Buy" from AnalystsBio-Rad Laboratories, Inc. (BIO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 15 at 1:46 AM
Rating on Bio Rad Laboratories (BIO) Raised to Strong Buy From a BuyRating on Bio Rad Laboratories (BIO) Raised to Strong Buy From a Buy
investorplace.com - November 9 at 1:49 PM
BIO Crosses Above Average Analyst TargetBIO Crosses Above Average Analyst Target
www.nasdaq.com - November 7 at 7:18 PM
Bio-Rad Laboratories, Inc. (BIO) Upgraded by Zacks Investment Research to HoldBio-Rad Laboratories, Inc. (BIO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - November 7 at 5:18 PM
Bio-Rad posts 3Q profitBio-Rad posts 3Q profit
finance.yahoo.com - November 6 at 5:35 PM
$628.03 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter$628.03 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter
www.americanbankingnews.com - November 5 at 6:22 AM
Bio-Rad Laboratories, Inc. (BIO) Expected to Post Earnings of $1.76 Per ShareBio-Rad Laboratories, Inc. (BIO) Expected to Post Earnings of $1.76 Per Share
www.americanbankingnews.com - November 3 at 11:19 PM
Bio-Rad Laboratories, Inc. (BIO) Issues  Earnings ResultsBio-Rad Laboratories, Inc. (BIO) Issues Earnings Results
www.americanbankingnews.com - November 3 at 5:02 PM
Edited Transcript of BIO earnings conference call or presentation 2-Nov-17 9:00pm GMTEdited Transcript of BIO earnings conference call or presentation 2-Nov-17 9:00pm GMT
finance.yahoo.com - November 3 at 8:38 AM
Bio-Rad Laboratories (BIO) Q3 2017 Results - Earnings Call TranscriptBio-Rad Laboratories (BIO) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 10:11 PM
Bio-Rad tops Street 3Q forecastsBio-Rad tops Street 3Q forecasts
finance.yahoo.com - November 2 at 10:11 PM
Bio-Rad Reports Third-Quarter 2017 Financial ResultsBio-Rad Reports Third-Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 5:08 PM
Quant Score Makes Bio Rad Laboratories (BIO) a BuyQuant Score Makes Bio Rad Laboratories (BIO) a Buy
investorplace.com - November 2 at 12:54 PM
New Strong Sell Stocks for November 1stNew Strong Sell Stocks for November 1st
finance.yahoo.com - November 1 at 5:11 PM
Bio-Rad Laboratories, Inc. – Value Analysis (NYSE:BIO) : October 31, 2017Bio-Rad Laboratories, Inc. – Value Analysis (NYSE:BIO) : October 31, 2017
finance.yahoo.com - October 31 at 5:41 PM
Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : BIO-US : October 30, 2017Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : BIO-US : October 30, 2017
finance.yahoo.com - October 30 at 5:35 PM
ETFs with exposure to Bio-Rad Laboratories, Inc. : October 27, 2017ETFs with exposure to Bio-Rad Laboratories, Inc. : October 27, 2017
finance.yahoo.com - October 27 at 6:54 PM
Bio Rad Laboratories (BIO) a Buy on Solid Quant ScoreBio Rad Laboratories (BIO) a Buy on Solid Quant Score
investorplace.com - October 26 at 12:43 PM
Bio-Rad Laboratories, Inc. (BIO) to Release Quarterly Earnings on MondayBio-Rad Laboratories, Inc. (BIO) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 10:54 AM
Bio Rad Laboratories (BIO) a Buy on Strong Quant ScoreBio Rad Laboratories (BIO) a Buy on Strong Quant Score
investorplace.com - October 19 at 12:40 PM

SEC Filings

Bio-Rad Laboratories (NYSE:BIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Rad Laboratories (NYSE:BIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Rad Laboratories (NYSE BIO) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.